Cargando…
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG
Antibody therapy of cancer is increasingly used in the clinic and has improved patient's life expectancy. Except for immune checkpoint inhibition, the mode of action of many antibodies is to recognize overexpressed or specific tumor antigens and initiate either direct F(ab′)(2)-mediated tumor c...
Autores principales: | Brandsma, Arianne M., Bondza, Sina, Evers, Mitchell, Koutstaal, Rosanne, Nederend, Maaike, Jansen, J. H. Marco, Rösner, Thies, Valerius, Thomas, Leusen, Jeanette H. W., ten Broeke, Toine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470253/ https://www.ncbi.nlm.nih.gov/pubmed/31031746 http://dx.doi.org/10.3389/fimmu.2019.00704 |
Ejemplares similares
-
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020) -
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021) -
IgA EGFR antibodies mediate tumour killing in vivo
por: Boross, Peter, et al.
Publicado: (2013) -
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020) -
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022)